Oncoinvent ASA
Biotechnology ResearchOslo, Norway51-200 Employees
Oncoinvent ASA is a clinical-stage biotechnology company based in Oslo, Norway, focused on radiopharmaceutical therapies for cancer. Its lead candidate, Radspherin, is an alpha-emitting microsphere suspension designed to treat metastatic cancers that spread to body cavities, with preclinical studies showing activity at doses that are essentially non-toxic. The company also advances radiotherapeutic and radioimmunotherapeutic programs centered on alpha-emitting radionuclides for solid tumors, supported by facilities capable of cGMP-compliant laboratory work and radiopharmaceutical production for clinical trials and research. The firm operates as a mid-sized biotechnology company targeting oncology patients with localized radiation approaches to minimize systemic exposure, including strategies that leverage the abdominal cavity to address residual micrometastases with a single localized alpha dose. In 2025 Oncoinvent merged with BerGenBio AS, a development that reflects strategic consolidation in the cancer radiopharmaceutical field.
1-888-653-2347 
support@leadiq.com 
